Compare Incyte Corporation (INCY) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Simon Property Group Inc — how do they compare? Incyte Corporation trades at $117.98 (market cap $23.11B), while Simon Property Group Inc trades at $227.33 (market cap $74.00B). The key difference: Simon Property Group Inc is far larger — about 3.2× Incyte Corporation's market cap, and Simon Property Group Inc pays a 3.86% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | SPG | |
|---|---|---|
Market Cap | $23.11B | $74.00B |
Sector | Health | Real Estate |
52-Week High | $118.52 | $228.70 |
52-Week Low | $67.38 | $160.68 |
Enterprise Value | $19.13B | $102.48B |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SPG trades at $228.53, down 0.07% on the day, with strong technical momentum showing bullish moving averages and neutral oscillators. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $1.48 versus $1.46, maintaining a three-quarter beat streak. Revenue growth continues from $6.0B in 2024 to $6.4B in 2025, supported by strong leasing activity and portfolio redevelopment. The stock offers a 4% dividend yield with recent H1-26 payment of $2.25 declared.
SPG presents a compelling investment case with strong operational performance and upward earnings revisions, though elevated valuation metrics and significant long-term debt of $24.21B warrant caution. Analyst consensus leans positive with 40.5% buy ratings but mixed sentiment reflects concerns about e-commerce competition and interest rate sensitivity. The current price sits above the $214.40 consensus target, suggesting limited near-term upside potential despite solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
